Jupiter Endovascular

Jupiter Endovascular company information, Employees & Contact Information

Imagine a world where you could bring the precision and control of surgery to catheter-based therapies. For decades, endovascular procedures have been constrained by the technological limitations of catheters that lose stability and control within the anatomy. We have created a new class of therapies to overcome these constraints by using Endoportal Control to mimic the precision and control of direct surgical access, while maintaining the minimally invasive profile of an endovascular intervention. Our vision is big, spanning the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients. Jupiter Endovascular is a medical technology startup located in the San Francisco Bay Area, led by a team of successful medical device entrepreneurs. We have big ambitions, with a culture built on innovation, teamwork, and speed. We have raised capital from a diversified investor base, including venture capital, private equity, corporate strategic investors, and clinician angel investors.

Company Details

Employees
41
Address
155 Jefferson Dr,
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
Keywords
Engineer jobs.
HQ
Menlo Park, California
Looking for a particular Jupiter Endovascular employee's phone or email?

Jupiter Endovascular Questions

News

AdvaMed Code of Ethics® - AdvaMed® - Advanced Medical Technology Association®

AdvaMed Code of Ethics® AdvaMed® - Advanced Medical Technology Association®

Jupiter Endovascular Announces Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025 - FinancialContent

Jupiter Endovascular Announces Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025 FinancialContent

FDA Approves Jupiter Endo Pivotal Trial for Pulmonary Embolism - Diagnostic and Interventional Cardiology

FDA Approves Jupiter Endo Pivotal Trial for Pulmonary Embolism Diagnostic and Interventional Cardiology

Surpassing $40M, Jupiter Endovascular Closes Oversubscribed Series B to fund SPIRARE II pivotal trial - Stock Titan

Surpassing $40M, Jupiter Endovascular Closes Oversubscribed Series B to fund SPIRARE II pivotal trial Stock Titan

Jupiter Endovascular Appoints Fred Ong as Chief Financial Officer - Business Wire

Jupiter Endovascular Appoints Fred Ong as Chief Financial Officer Business Wire

Jupiter Endovascular Announces First U.S. Patient Treated With Vertex Pulmonary Embolectomy System Using Endoportal Control - Business Wire

Jupiter Endovascular Announces First U.S. Patient Treated With Vertex Pulmonary Embolectomy System Using Endoportal Control Business Wire

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism - Business Wire

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism Business Wire

Top Jupiter Endovascular Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant